{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019191", "CSN": null, "TRF": "ORD_1310401_01", "MRN": "28253476", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1048176", "clinicalId": "1049547", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1310401_01", "SampleName": "US1259521.01", "Version": "0", "Sample": {"FM_Id": "ORD_1310401_01", "SampleId": "US1259521.01", "BlockId": "nan", "TRFNumber": "ORD_1310401_01", "TestType": "FoundationOne Liquid  ", "SpecFormat": "Blood", "ReceivedDate": "2022_02_25", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "18", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98576", "MRN": "28253476", "FullName": "\u5f90\u79c0\u73e0", "FirstName": "28253476", "LastName": "28253476", "SubmittedDiagnosis": "Liver cholangiocarcinoma", "Gender": "Female", "DOB": "1949_08_01", "OrderingMD": "\u9673\u660e\u6643", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Blood", "CollDate": "2022_02_23", "ReceivedDate": "2022-03-09 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Cholangiocarcinoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "13", "clinicalTrialCount": "18", "resistiveCount": "0", "sensitizingCount": "3"}, "VariantProperties": {"VariantProperty": [{"geneName": "APC", "isVUS": "true", "variantName": "R94S"}, {"geneName": "CDK12", "isVUS": "true", "variantName": "T1161M"}, {"geneName": "CXCR4", "isVUS": "true", "variantName": "I142T"}, {"geneName": "GATA4", "isVUS": "true", "variantName": "A179_S180insA"}, {"geneName": "MSH3", "isVUS": "true", "variantName": "R296C"}, {"geneName": "TEK", "isVUS": "true", "variantName": "G743A"}, {"geneName": "TET2", "isVUS": "true", "variantName": "A1159P"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ARID1A", "Include": "true", "Alterations": {"Alteration": {"Name": "S460fs*163", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "S460fs*163"}}, "Interpretation": "ARID1A encodes the AT_rich interactive domain_containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan_On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46_50%), ovarian and uterine endometrioid carcinomas (24_44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, Jan 2022) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). ARID1A protein loss is associated with tumors of poor histological grade for many tumor types, including colorectal cancer (CRC) (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809), cervical cancer (Katagiri et al., 2012; 22274316, Cho et al., 2013; 23427874), gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857), urothelial carcinoma (Gui et al., 2011; 21822268, Balbas_Martinez et al., 2013; 23650517, Faraj et al., 2014; 25175170), ovarian and endometrial cancers (Rahman et al., 2013; 22939958, Maeda et al., 2010; 21614196, Lowery et al., 2012; 22193641, Fadare et al., 2013; 23524907, Mao et al., 2013; 24076775, Katagiri et al., 2012; 22101352, Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303), breast carcinoma (Zhang et al., 2012; 21889920, Mamo et al., 2012; 21892209, Zhao et al., 2014; 24430365), and clear cell renal cell carcinoma (Lichner et al., 2013; 23416164); ARID1A mutation has been associated with poor outcomes for patients with cholangiocarcinoma (Feng et al., 2021; 33387086, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Ruzzenente et al., 2016; 26717940). However, prognostic data regarding patient survival are often mixed and conflicting. There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib (Williamson et al., 2016; 27958275). In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib (Aggarwal et al., 2021; ESMO Abstract 512O). One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124). In a Phase 1 trial, a patient with metastatic colorectal cancer harboring both an ARID1A mutation and ATM loss treated with single_agent M6620 achieved a CR that was ongoing at 29 months (Yap et al., 2020; 32568634). On the basis of limited preclinical evidence from studies in ovarian cancer, ARID1A inactivation may predict sensitivity to EZH2 inhibitors (Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009), which are under investigation in clinical trials. Other studies have reported that the loss of ARID1A may activate the PI3K_AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti_PD_1 or anti_PD_L1 immunotherapy (Okamura et al., 2020; 32111729). Loss of ARID1A expression has been associated with chemoresistance to platinum_based therapy for patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5_fluorouracil in colorectal cancer cell lines (Xie et al., 2014; 24833095).", "Include": "true", "ClinicalTrialNote": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04768296", "Include": "true"}, {"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04657068", "Include": "true"}, {"nctId": "NCT04802174", "Include": "true"}, {"nctId": "NCT02595931", "Include": "true"}, {"nctId": "NCT04514497", "Include": "true"}, {"nctId": "NCT04266912", "Include": "true"}, {"nctId": "NCT03669601", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "FGFR2", "Include": "true", "Alterations": {"Alteration": {"Name": "FGFR2_BICC1 fusion", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "FGFR2_BICC1 fusion"}}, "Interpretation": "FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis (Powers et al., 2000; 11021964, Turner and Grose, 2010; 20094046). FGFR2 fusions retaining the kinase domain encoded by exons 11_17 have been reported to be activating, oncogenic, and sensitive to FGFR inhibitors (Singh et al., 2012; 22837387, Lorenzi et al., 1996; 8799135, Wu et al., 2013; 23558953, Arai et al., 2013; 24122810, Wu et al., 2013; 23558953). Furthermore, FGFR2 variants lacking a portion of the cytoplasmic domain encoded by exon 18 have been reported to be oncogenic in vitro (Lorenzi et al., 1997; 9266968, Lorenzi et al., 1996; 8799135, Ueda et al., 1999; 10626794, Wu et al., 2013; 23558953, Cha et al., 2009; 19103595). Rearrangements such as observed here are predicted to be activating. FGFR2 alterations, predominantly fusions, have been reported in 8_50% of intrahepatic cholangiocarcinomas (Javle et al., 2016; 27622582, Ross et al., 2014; 24563076, Borad et al., 2014; 24550739, Arai et al., 2013; 24122810, Sia et al., 2015; 25608663, cBio_Jiao et al., 2013; 24185509, Nakamura et al., 2015; 26258846). In contrast, FGFR2 fusions were not identified in studies of patients with extrahepatic cholangiocarcinoma (Lee et al., 2015; 26500333, Nakamura et al., 2015; 26258846). Although FGFR2 translocations were associated with favorable prognosis for patients with intrahepatic cholangiocarcinoma in 2 retrospective studies (Graham et al., 2014; 24837095, Javle et al., 2016; 27622582), no association was observed in 2 others (Boerner et al., 2021; 33765338, Pu et al., 2020; 32825971). In patients with cholangiocarcinoma harboring FGFR2 fusions, the presence of co_occurring mutations in CDKN2A/B, PBRM1, or TP53 was associated with significantly shorter PFS on pemigatinib (p=0.05) (Silverman et al., 2021; 33218975). FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117), pemigatinib (Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698, Kuboki et al., 2019; JSMO Abstract P1_156), infigratinib (Nogova et al., 2016; 27870574, Javle et al., 2021; ASCO GI Abstract 265), E7090 (Morizane et al., 2020; ASCO GI Abstract 538), AZD4547 (Pearson et al., 2016; 27179038, Van Cutsem et al., 2017; 29177434, Aggarwal et al., 2019; 31195180, Chae et al., 2018; ASCO Abstract 2503), Debio 1347 (Voss et al., 2019; 30745300, Clearly et al., 2021; 33926920), rogaratinib (Schuler et al., 2019; 31405822), futibatinib (Bahleda et al., 2018; AACR Abstract CT121, Goyal et al., 2019; 31109923, Tran et al., 2018; ESMO Abstract 155O), ICP192 (Guo et al., 2021; ASCO Abstract 4092), and derazantinib (Mazzaferro et al., 2019; 30420614) as well as to the multikinase inhibitors pazopanib (Borad et al., 2014; 24550739, Liao et al., 2013; 23786770) and ponatinib (Gozgit et al., 2012; 22238366). In the context of FGFR2 rearrangement, FGFR inhibitors have primarily been investigated for patients with previously treated intrahepatic cholangiocarcinoma (ICC), with the Phase 2 FIGHT_202 trial for pemigatinib (Abou_Alfa et al., 2020; 32203698) and a Phase 2 trial for infigratinib (Javle et al., 2021; ASCO GI Abstract 265) respectively reporting ORRs of 36% (38/107) and 23% (25/108). The Phase 2 FOENIX_CCA2 trial of futibatinib in locally advanced or metastatic, unresectable intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements reported a 42% (43/103) ORR, 83% (85/103) DCR, 9.7_month median duration of response, 9.0_month median PFS, and 21.7_month median OS (Goyal et al., 2021; AACR Abstract CT010). A case series described 4 patients with FGFR2 fusion_positive ICC that exhibited PR (2) or SD (2) following treatment with futibatinib after initially progressing on infigratinib or Debio_1347; ctDNA analysis revealed the loss of FGFR2 kinase domain mutations while on futibatinib but also the emergence of additional mutations, including V564F (also known as V565F) (Goyal et al., 2019; 31109923). A Phase 1/2 study of derazantinib for the treatment of FGFR2 fusion_positive inoperable ICC reported an ORR of 21% (6/29 PRs) and mPFS of 5.7 months (Mazzaferro et al., 2019; 30420614).", "Include": "true", "ClinicalTrialNote": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Erdafitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Erdafitinib is a pan_fibroblast growth factor receptor (FGFR) inhibitor. It is FDA approved for the treatment of patients with advanced or metastatic urothelial carcinoma who have FGFR2 or FGFR3 alterations and have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence for FGFR2 fusions (Tabernero et al., 2015; 26324363, Siefker_Radtke et al., 2018; ASCO Abstract 4503, Park et al., 2019; ASCO Abstract 4117), limited evidence for FGFR2 mutations (Soria et al., 2017; ASCO Abstract 4074, Park et al., 2019; ASCO Abstract 4117) and limited evidence for FGFR2 amplification (Bahleda et al., 2019; 31088831), and preclinical data (Perera et al., 2017; 28341788, Karkera et al., 2017; 28416604), FGFR2 activating alterations may confer sensitivity to erdafitinib. </p> <p><b>Supporting Data:</b> A Phase 2a study of erdafitinib for previously treated patients with FGFR_altered advanced cholangiocarcinoma (CCA) reported 47% (7/15) PRs and a median PFS of 5.6 months; for FGFR2_ or FGFR3_fusion_positive CCA, there were 33% (6/9) PRs and a median PFS of 12.7 months (Park et al., 2019; ASCO Abstract 4117). A Phase 1 study for erdafitinib in solid tumors reported a better response in tumors carrying FGFR mutations or gene fusions compared to the overall cohort, with an ORR of 21% (19/92) vs 11% (21/187), respectively (Bahleda et al., 2019; 31088831). The most responsive tumor types for patients with FGFR mutations or fusions in this study were urothelial carcinoma and cholangiocarcinoma, with an ORR of 46% (12/26) and 27% (3/11), respectively; however, a patient with gallbladder carcinoma did not respond to erdafitinib in this study (Bahleda et al., 2019; 31088831). Of patients with FGFR altered CCA treated with erdafitinib in another Phase 1 study, including 1 patient with FGFR2 mutation and 2 patients with FGFR2 fusions, 27% (3/11) exhibited PRs; the median duration of response was 11.4 months, and an additional 27% (3/11) patients exhibited SD (Soria et al., 2016; ASCO Abstract 4074). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Infigratinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Infigratinib is a TKI that inhibits FGFR1, FGFR2, and FGFR3. It is FDA approved for the treatment of patients with unresectable locally advanced or metastatic cholangiocarcinoma who have FGFR2 rearrangements or fusions and have progressed after prior therapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> Based on clinical activity in cholangiocarcinoma (Javle et al., 2021; ASCO GI Abstract 265), FGFR2 fusions or rearrangements may predict sensitivity to infigratinib. </p> <p><b>Supporting Data:</b> A Phase 2 study of single_agent infigratinib reported a 23.1% ORR (25/108; 1 CR, 24 PR), 5.0 month median duration of response, and 84.3% DCR (91/108) for patients with recurrent cholangiocarcinoma harboring an FGFR2 fusion or rearrangement; the median PFS and OS were 7.3 and 12.2 months, respectively (Javle et al., 2021; ASCO GI Abstract 265). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Pemigatinib", "FDAApproved": "true", "Rationale": "<p><b>Approved Indications:</b> Pemigatinib is FDA approved for the treatment of patients with advanced or metastatic cholangiocarcinoma who have FGFR2 rearrangements or fusions and have progressed after prior chemotherapy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of strong clinical evidence and preclinical data for FGFR2 fusions, FGFR2 rearrangements may confer sensitivity to pemigatinib (Vogel et al. 2019; ESMO Abstract LBA40, Bibeau et al. 2020; ASCO GI Abstract 588, Hollebecque et al., 2019; ESMO Abstract 720P, Krook et al., 2019; 31371345, Abou_Alfa et al., 2020; 32203698). </p> <p><b>Supporting Data:</b> The Phase 2 FIGHT_202 study of pemigatinib for previously treated patients with FGFR2_rearranged advanced cholangiocarcinoma (CCA) reported a longer median OS (21.1 months vs. 6.7 vs. 4.0 months), longer median PFS (6.9 months vs. 2.1 vs. 1.7 months), and a higher ORR (36% [38/107, 3 CRs] vs. 0% vs. 0%) than those with or without FGF/FGFR alterations (Vogel et al., 2019; ESMO abstract LBA40, Hollebecque et al., 2019; ESMO Abstract 720P, Abou_Alfa et al., 2020; 32203698, Silverman et al., 2021; 33218975). A Phase 1/2 FIGHT_101 study of pemigatinib for patients with FGFR_altered tumors reported 1 PR of 5.5 months for a patient with CCA and an FGFR2_CLIP1 fusion (Krook et al., 2019; 31371345). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03773302", "Include": "true"}, {"nctId": "NCT04083976", "Include": "true"}, {"nctId": "NCT04093362", "Include": "true"}, {"nctId": "NCT04238715", "Include": "true"}, {"nctId": "NCT03656536", "Include": "true"}, {"nctId": "NCT05010668", "Include": "true"}, {"nctId": "NCT05010681", "Include": "true"}, {"nctId": "NCT04550624", "Include": "true"}, {"nctId": "NCT03758664", "Include": "true"}, {"nctId": "NCT04189445", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Blood Tumor Mutational Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "01", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "01"}}, "Interpretation": "Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Aggarwal et al., 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered. Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2021). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study (Nakamura et al., 2015; 26258846), TMB_high (\u226510 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB_high tumors experienced numerically longer OS compared with patients with TMB_low tumors (11.5 vs. 8.4 months, adjusted HR=0.65) (Shao et al., 2020; 33119110). On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Socinski et al., 2019 ESMO Abstract LBA83, Gandara et al., 2018; 30082870, Wang et al., 2019; 30816954, Li et al., 2020; ASCO Abstract 6511) and anti_PD_1 (Aggarwal et al., 2020; 32102950, Peters et al., 2019; AACR Abstract CT074) therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb (Gandara et al., 2018; 30082870, Socinski et al., 2019 ESMO Abstract LBA83, Aggarwal et al. 2020; 32102950, Rizvi et al., 2019; ASCO Abstract 9016). In HNSCC, a Phase 3 trial showed that bTMB \u226516 Muts/Mb (approximate equivalency \u22658 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD_L1 inhibitor alone or in combination with a CTLA_4 inhibitor (Li et al., 2020; ASCO Abstract 6511).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "Cannot Be Determined", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Cannot Be Determined"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). The level of MSI in this sample could not be determined with confidence. Depending on the clinical context, MSI testing of an alternate sample or by another methodology could be considered. MSI_H is infrequent in cholangiocarcinoma, reported in 1% of samples (Javle et al., 2019; ASCO Abstract 4087). A non_zero level of MSI has been reported in 18_49% of cholangiocarcinoma cases (Momoi et al., 2001; 11580146, Limpaiboon et al., 2002; 12175538, Liu et al., 2002; 12402306, Liengswangwong et al., 2003; 14506736), although the studies did not specify what fraction of cases were MSI_H. A higher frequency of MSI (63%) was reported in patients with intrahepatic cholangiocarcinoma associated with exposure to Thorotrast (Liu et al., 2002; 12402306). One study reported that MSI is associated with poor prognosis in liver fluke_related cholangiocarcinoma (Limpaiboon et al., 2002; 12175538). On the basis of prospective clinical evidence in multiple solid tumor types, microsatellite instability (MSI) and associated increased tumor mutational burden (TMB) (Jass, 2007; 17204026, Lal et al., 2015; 25949894) may predict sensitivity to immune checkpoint inhibitors, including the approved PD_1_targeting agents cemiplimab, dostarlimab, nivolumab (alone or in combination with ipilimumab), and pembrolizumab (Overman et al., 2017; 28734759, Overman et al., 2018; 29355075, Overman et al., 2019; ASCO Abstract 635, Lipson et al., 2013; 23169436, Le et al., 2015; 26028255, Rizvi et al., 2015; 25765070, Oaknin et al., 2020; 33001143) and PD_L1_targeting agents atezolizumab, avelumab, and durvalumab (Hochster et al., 2017; ASCO Abstract 673, Fleming et al., 2018; ASCO Abstract 5585, Bang et al., 2018; ASCO Abstract 92). As the MSI status of this tumor is unknown, the relevance of these therapeutic approaches is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "P151S", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "P151S"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25_63% of gallbladder carcinomas and 10_61% of cholangiocarcinomas (Li et al., 2014; 24997986, Ross et al., 2014; 24563076, Jiao et al., 2013; 24185509, Chan_On et al., 2013; 24185513, Borger et al., 2012; 22180306, Suto et al., 2000; 10738270, Ong et al., 2012; 22561520, Javle et al., 2016; 27622582, Nakamura et al., 2015; 26258846, Nault and Zucman_Rossi, 2011; 21538283). TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%) (Chan_On et al., 2013; 24185513). Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20\u201362% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas (Won et al., 2010; 20955617, Chaube et al., 2006; 16686942, Chuang et al., 2004; 15573254). Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting (Ruzzenente et al., 2016; 26717940, Xiaofang et al., 2012; 22230750, Ajiki et al., 1996; 8799388, Saetta, 2006; 16724348, Guo et al., 2014; 24746206, Boerner et al., 2021; 33765338, Conci et al., 2020; 32020551, Simbolo et al., 2018; 29740198, Churi et al., 2014; 25536104). Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers (Lee and Pirdas, 1995; 7567135, Ahrendt et al., 2000; 11180865); however, another study did not find such a correlation (Ajiki et al., 1996; 8799388). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Fraction", "Include": "true", "Alterations": {"Alteration": {"Name": "Elevated Tumor Fraction", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "Elevated Tumor Fraction"}}, "Interpretation": "Tumor fraction provides an estimate of the percentage of ctDNA present in a cell_free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single_nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content (Li et al., 2019; 31602320), the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy (Zhang et al., 2020; 32757294, Butler et al., 2019; 30833418). Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3) (Bettegowda et al., 2014; 24553385). Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer (Lapin et al., 2018; 30400802), Ewing sarcoma and osteosarcoma (Shulman et al., 2018; 30131550), prostate cancer (Choudhury et al., 2018; 30385733, Conteduca et al., 2019; ASCO abstract 5039), breast cancer (Stover et al., 2018; 29298117), leiomyosarcoma (Hemming et al., 2019; 30793095), esophageal cancer (Egyud et al., 2019; 31059681), colorectal cancer (Fan et al., 2017; 28187169), and gastrointestinal cancer (Vu et al., 2020; DOI: 10.1200/PO.19.00204). Specimens with elevated tumor fraction have high circulating_tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management (Bronkhorst et al., 2019; 30923679, Raja et al., 2018; 30093454, Hrebien et al., 2019; 30860573, Conteduca et al., 2019; ASCO Abstract 5039, Choudhury et al., 2018; 30385733, Goodall et al., 2017; 28450425, Goldberg et al., 2018; 29330207).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "Berzosertib + Topotecan in Relapsed Platinum_Resistant Small_Cell Lung Cancer (DDRiver SCLC 250)", "StudyPhase": "PHASE 2", "Target": "TOP1, ATR", "Locations": "Hangzhou (China), Nanjing (China), Wuhan (China), Xi an (China), Osaka (Japan), Beijing (China), Hirakata_shi (Japan), Takatsuki_shi (Japan), Chengdu (China), Chuo_ku (Japan)", "NCTID": "NCT04768296", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)", "NCTID": "NCT02264678", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "London (United Kingdom), Colorado, Oklahoma, Tennessee, Florida", "NCTID": "NCT04657068", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High_Grade Neuroendocrine Cancers", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "Maryland", "NCTID": "NCT04802174", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "ATR Kinase Inhibitor VX_970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "California, Missouri, Pennsylvania, Massachusetts, Connecticut, Tennessee", "NCTID": "NCT02595931", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "ATR, TOP1", "Locations": "Arizona, Oklahoma, Connecticut, Tennessee, Florida", "NCTID": "NCT04514497", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PD_L1", "Locations": "Texas", "NCTID": "NCT04266912", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "S460fs*163", "Title": "AZD6738 & Gemcitabine as Combination Therapy", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "Cambridge (United Kingdom)", "NCTID": "NCT03669601", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "Study of Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations", "StudyPhase": "PHASE 3", "Target": "FGFR3, FGFR1, FGFR2", "Locations": "Taipei (Taiwan), Taoyuan City (Taiwan), Taichung City (Taiwan), Huwei (Taiwan), Tainan (Taiwan), Tainan City (Taiwan), Kaohsiung (Taiwan), Pusan (Korea, Republic of), Suwon_si (Korea, Republic of), Seongnam_si (Korea, Republic of)", "NCTID": "NCT03773302", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations", "StudyPhase": "PHASE 2", "Target": "FGFRs", "Locations": "Taipei (Taiwan), Taoyuan City (Taiwan), Taichung (Taiwan), Changhua (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Kaohsiung (Taiwan), Hangzhou (China), Shanghai (China), Nanjing (China)", "NCTID": "NCT04083976", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "Futibatinib Versus Gemcitabine_Cisplatin Chemotherapy as First_Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements", "StudyPhase": "PHASE 3", "Target": "FGFRs", "Locations": "Taipei (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Busan (Korea, Republic of), Shatin (Hong Kong), Hong Kong (Hong Kong), Nagasaki_shi (Japan), Hwasun (Korea, Republic of), Fukuoka_shi (Japan), Daegu (Korea, Republic of)", "NCTID": "NCT04093362", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion", "StudyPhase": "PHASE 2", "Target": "FGFR1, FGFR2, FGFR3", "Locations": "Fuzhou (China), Xiamen (China), Ningbo (China), Hangzhou (China), Shanghai (China), Suzhou (China), Nantong (China), Shenzhen (China), Nanjing (China), Hefei (China)", "NCTID": "NCT04238715", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma _ (FIGHT_302)", "StudyPhase": "PHASE 3", "Target": "FGFR1, FGFR2, FGFR3", "Locations": "Hangzhou (China), Shanghai (China), SHanghai (China), Nanjing (China), Yangzhou (China), Guangzhou (China), Wuhan (China), Fukuoka (Japan), Fukuoka_shi (Japan), Yufu_shi (Japan)", "NCTID": "NCT03656536", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma", "StudyPhase": "PHASE 2", "Target": "FGFRs, RET, PDGFRA, VEGFRs, KIT, PD_1", "Locations": "Shanghai (China)", "NCTID": "NCT05010668", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer", "StudyPhase": "PHASE 2", "Target": "PD_1, FGFRs, RET, PDGFRA, VEGFRs, KIT", "Locations": "Shanghai (China)", "NCTID": "NCT05010681", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Cholangiocarcinoma", "StudyPhase": "PHASE 2", "Target": "PD_1, KIT, VEGFRs, FGFRs, PDGFRA, RET", "Locations": "Shanghai (China)", "NCTID": "NCT04550624", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "Clinical Study of ICP_192 in Solid Tumors Patients", "StudyPhase": "PHASE 1/2", "Target": "FGFR2, FGFR1, FGFR3, FGFR4", "Locations": "Shanghai (China)", "NCTID": "NCT03758664", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}, {"Gene": "FGFR2", "Alteration": "FGFR2_BICC1 fusion", "Title": "Futibatinib in Patients With Specific FGFR Aberrations", "StudyPhase": "PHASE 2", "Target": "FGFRs", "Locations": "Jordon (Hong Kong), Hong Kong (Hong Kong), Matsuyama_shi (Japan), Seongnam (Korea, Republic of), Seul (Korea, Republic of), Seoul (Korea, Republic of), Suita_shi (Japan), Nagoya_shi (Japan), Chuo_ku (Japan), Kashiwa_shi (Japan)", "NCTID": "NCT04189445", "Note": "FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21900401", "FullCitation": "Guan B, et al. Cancer Res. (2011) pmid: 21900401", "Include": "true"}, {"number": "1", "ReferenceId": "22009941", "FullCitation": "Jones S, et al. Hum. Mutat. (2012) pmid: 22009941", "Include": "true"}, {"number": "2", "ReferenceId": "20942669", "FullCitation": "Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669", "Include": "true"}, {"number": "3", "ReferenceId": "20826764", "FullCitation": "Jones S, et al. Science (2010) pmid: 20826764", "Include": "true"}, {"number": "4", "ReferenceId": "24293408", "FullCitation": "Yan HB, et al. Carcinogenesis (2014) pmid: 24293408", "Include": "true"}, {"number": "5", "ReferenceId": "22808142", "FullCitation": "Wang DD, et al. PLoS ONE (2012) pmid: 22808142", "Include": "true"}, {"number": "6", "ReferenceId": "22922871", "FullCitation": "Huang J, et al. Nat. Genet. (2012) pmid: 22922871", "Include": "true"}, {"number": "7", "ReferenceId": "24185513", "FullCitation": "Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513", "Include": "true"}, {"number": "8", "ReferenceId": "21892209", "FullCitation": "Mamo A, et al. Oncogene (2012) pmid: 21892209", "Include": "true"}, {"number": "9", "ReferenceId": "22484628", "FullCitation": "Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628", "Include": "true"}, {"number": "10", "ReferenceId": "22037554", "FullCitation": "Wang K, et al. Nat. Genet. (2011) pmid: 22037554", "Include": "true"}, {"number": "11", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "12", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "13", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "14", "ReferenceId": "24618703", "FullCitation": "Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703", "Include": "true"}, {"number": "15", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "16", "ReferenceId": "23318448", "FullCitation": "Streppel MM, et al. Oncogene (2014) pmid: 23318448", "Include": "true"}, {"number": "17", "ReferenceId": "24293293", "FullCitation": "Jiao Y, et al. J. Pathol. (2014) pmid: 24293293", "Include": "true"}, {"number": "18", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "19", "ReferenceId": "25195947", "FullCitation": "Huang HN, et al. Histopathology (2015) pmid: 25195947", "Include": "true"}, {"number": "20", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "21", "ReferenceId": "23702729", "FullCitation": "Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729", "Include": "true"}, {"number": "22", "ReferenceId": "23887303", "FullCitation": "Allo G, et al. Mod. Pathol. (2014) pmid: 23887303", "Include": "true"}, {"number": "23", "ReferenceId": "32111729", "FullCitation": "Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729", "Include": "true"}, {"number": "24", "ReferenceId": "24925223", "FullCitation": "Chou A, et al. Hum. Pathol. (2014) pmid: 24925223", "Include": "true"}, {"number": "25", "ReferenceId": "25311944", "FullCitation": "Ye J, et al. Hum. Pathol. (2014) pmid: 25311944", "Include": "true"}, {"number": "26", "ReferenceId": "25561809", "FullCitation": "Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809", "Include": "true"}, {"number": "27", "ReferenceId": "25583476", "FullCitation": "Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476", "Include": "true"}, {"number": "28", "ReferenceId": "22915242", "FullCitation": "Abe H, et al. Virchows Arch. (2012) pmid: 22915242", "Include": "true"}, {"number": "29", "ReferenceId": "24767857", "FullCitation": "Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857", "Include": "true"}, {"number": "30", "ReferenceId": "22274316", "FullCitation": "Katagiri A, et al. Int. J. Gynecol. Cancer (2012) pmid: 22274316", "Include": "true"}, {"number": "31", "ReferenceId": "23427874", "FullCitation": "Cho H, et al. Hum. Pathol. (2013) pmid: 23427874", "Include": "true"}, {"number": "32", "ReferenceId": "21822268", "FullCitation": "Gui Y, et al. Nat. Genet. (2011) pmid: 21822268", "Include": "true"}, {"number": "33", "ReferenceId": "23650517", "FullCitation": "Balb\u00e1s_Mart\u00ednez C, et al. PLoS ONE (2013) pmid: 23650517", "Include": "true"}, {"number": "34", "ReferenceId": "25175170", "FullCitation": "Faraj SF, et al. Hum. Pathol. (2014) pmid: 25175170", "Include": "true"}, {"number": "35", "ReferenceId": "22939958", "FullCitation": "Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958", "Include": "true"}, {"number": "36", "ReferenceId": "21614196", "FullCitation": "Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196", "Include": "true"}, {"number": "37", "ReferenceId": "22193641", "FullCitation": "Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641", "Include": "true"}, {"number": "38", "ReferenceId": "23524907", "FullCitation": "Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907", "Include": "true"}, {"number": "39", "ReferenceId": "24076775", "FullCitation": "Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775", "Include": "true"}, {"number": "40", "ReferenceId": "22101352", "FullCitation": "Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352", "Include": "true"}, {"number": "41", "ReferenceId": "21889920", "FullCitation": "Zhang X, et al. Cancer Epidemiol (2012) pmid: 21889920", "Include": "true"}, {"number": "42", "ReferenceId": "24430365", "FullCitation": "Zhao J, et al. Tumour Biol. (2014) pmid: 24430365", "Include": "true"}, {"number": "43", "ReferenceId": "23416164", "FullCitation": "Lichner Z, et al. Am. J. Pathol. (2013) pmid: 23416164", "Include": "true"}, {"number": "44", "ReferenceId": "33387086", "FullCitation": "Feng F, et al. Int J Clin Oncol (2021) pmid: 33387086", "Include": "true"}, {"number": "45", "ReferenceId": "32020551", "FullCitation": "Conci S, et al. Updates Surg (2020) pmid: 32020551", "Include": "true"}, {"number": "46", "ReferenceId": "29740198", "FullCitation": "Simbolo M, et al. Sci Rep (2018) pmid: 29740198", "Include": "true"}, {"number": "47", "ReferenceId": "26717940", "FullCitation": "Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940", "Include": "true"}, {"number": "48", "ReferenceId": "27958275", "FullCitation": "Williamson CT, et al. Nat Commun (2016) pmid: 27958275", "Include": "true"}, {"number": "49", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "50", "ReferenceId": "32568634", "FullCitation": "Yap TA, et al. J Clin Oncol (2020) pmid: 32568634", "Include": "true"}, {"number": "51", "ReferenceId": "25686104", "FullCitation": "Bitler BG, et al. Nat. Med. (2015) pmid: 25686104", "Include": "true"}, {"number": "52", "ReferenceId": "26552009", "FullCitation": "Kim KH, et al. Nat. Med. (2015) pmid: 26552009", "Include": "true"}, {"number": "53", "ReferenceId": "24559118", "FullCitation": "Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118", "Include": "true"}, {"number": "54", "ReferenceId": "24336158", "FullCitation": "Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158", "Include": "true"}, {"number": "55", "ReferenceId": "24979463", "FullCitation": "Samartzis EP, et al. Oncotarget (2014) pmid: 24979463", "Include": "true"}, {"number": "56", "ReferenceId": "24459582", "FullCitation": "Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582", "Include": "true"}, {"number": "57", "ReferenceId": "24833095", "FullCitation": "Xie C, et al. Tumour Biol. (2014) pmid: 24833095", "Include": "true"}, {"number": "58", "ReferenceId": "11021964", "FullCitation": "Powers CJ, et al. Endocr. Relat. Cancer (2000) pmid: 11021964", "Include": "true"}, {"number": "59", "ReferenceId": "20094046", "FullCitation": "Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046", "Include": "true"}, {"number": "60", "ReferenceId": "22837387", "FullCitation": "Singh D, et al. Science (2012) pmid: 22837387", "Include": "true"}, {"number": "61", "ReferenceId": "8799135", "FullCitation": "Lorenzi MV, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8799135", "Include": "true"}, {"number": "62", "ReferenceId": "23558953", "FullCitation": "Wu YM, et al. Cancer Discov (2013) pmid: 23558953", "Include": "true"}, {"number": "63", "ReferenceId": "24122810", "FullCitation": "Arai Y, et al. Hepatology (2014) pmid: 24122810", "Include": "true"}, {"number": "64", "ReferenceId": "9266968", "FullCitation": "Lorenzi MV, et al. Oncogene (1997) pmid: 9266968", "Include": "true"}, {"number": "65", "ReferenceId": "10626794", "FullCitation": "Ueda T, et al. Cancer Res. (1999) pmid: 10626794", "Include": "true"}, {"number": "66", "ReferenceId": "19103595", "FullCitation": "Cha JY, et al. J. Biol. Chem. (2009) pmid: 19103595", "Include": "true"}, {"number": "67", "ReferenceId": "27622582", "FullCitation": "Javle M, et al. Cancer (2016) pmid: 27622582", "Include": "true"}, {"number": "68", "ReferenceId": "24550739", "FullCitation": "Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739", "Include": "true"}, {"number": "69", "ReferenceId": "25608663", "FullCitation": "Sia D, et al. Nat Commun (2015) pmid: 25608663", "Include": "true"}, {"number": "70", "ReferenceId": "24185509", "FullCitation": "Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509", "Include": "true"}, {"number": "71", "ReferenceId": "26258846", "FullCitation": "Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846", "Include": "true"}, {"number": "72", "ReferenceId": "26500333", "FullCitation": "Lee H, et al. J. Clin. Pathol. (2016) pmid: 26500333", "Include": "true"}, {"number": "73", "ReferenceId": "24837095", "FullCitation": "Graham RP, et al. Hum Pathol (2014) pmid: 24837095", "Include": "true"}, {"number": "74", "ReferenceId": "33765338", "FullCitation": "Boerner T, et al. Hepatology (2021) pmid: 33765338", "Include": "true"}, {"number": "75", "ReferenceId": "32825971", "FullCitation": "Pu X, et al. Pathol Res Pract (2020) pmid: 32825971", "Include": "true"}, {"number": "76", "ReferenceId": "33218975", "FullCitation": "Silverman IM, et al. Cancer Discov (2021) pmid: 33218975", "Include": "true"}, {"number": "77", "ReferenceId": "26324363", "FullCitation": "Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363", "Include": "true"}, {"number": "78", "ReferenceId": "31371345", "FullCitation": "Krook MA, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 31371345", "Include": "true"}, {"number": "79", "ReferenceId": "32203698", "FullCitation": "Abou_Alfa GK, et al. Lancet Oncol. (2020) pmid: 32203698", "Include": "true"}, {"number": "80", "ReferenceId": "27870574", "FullCitation": "Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574", "Include": "true"}, {"number": "81", "ReferenceId": "27179038", "FullCitation": "Pearson A, et al. Cancer Discov (2016) pmid: 27179038", "Include": "true"}, {"number": "82", "ReferenceId": "29177434", "FullCitation": "Van Cutsem E, et al. Ann. Oncol. (2017) pmid: 29177434", "Include": "true"}, {"number": "83", "ReferenceId": "31195180", "FullCitation": "Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180", "Include": "true"}, {"number": "84", "ReferenceId": "30745300", "FullCitation": "Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300", "Include": "true"}, {"number": "85", "ReferenceId": "33926920", "FullCitation": "Cleary JM, et al. Cancer Discov (2021) pmid: 33926920", "Include": "true"}, {"number": "86", "ReferenceId": "31405822", "FullCitation": "Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822", "Include": "true"}, {"number": "87", "ReferenceId": "31109923", "FullCitation": "Goyal L, et al. Cancer Discov (2019) pmid: 31109923", "Include": "true"}, {"number": "88", "ReferenceId": "30420614", "FullCitation": "Mazzaferro V, et al. Br. J. Cancer (2019) pmid: 30420614", "Include": "true"}, {"number": "89", "ReferenceId": "23786770", "FullCitation": "Liao RG, et al. Cancer Res. (2013) pmid: 23786770", "Include": "true"}, {"number": "90", "ReferenceId": "22238366", "FullCitation": "Gozgit JM, et al. Mol. Cancer Ther. (2012) pmid: 22238366", "Include": "true"}, {"number": "91", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "92", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "93", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "94", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "95", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "96", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "97", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "98", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "99", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "100", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "101", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "102", "ReferenceId": "30082870", "FullCitation": "Gandara DR, et al. Nat. Med. (2018) pmid: 30082870", "Include": "true"}, {"number": "103", "ReferenceId": "30816954", "FullCitation": "Wang Z, et al. JAMA Oncol (2019) pmid: 30816954", "Include": "true"}, {"number": "104", "ReferenceId": "32102950", "FullCitation": "Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950", "Include": "true"}, {"number": "105", "ReferenceId": "33119110", "FullCitation": "Shao C, et al. JAMA Netw Open (2020) pmid: 33119110", "Include": "true"}, {"number": "106", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "107", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "108", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "109", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "110", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "111", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "112", "ReferenceId": "24997986", "FullCitation": "Li M, et al. Nat. Genet. (2014) pmid: 24997986", "Include": "true"}, {"number": "113", "ReferenceId": "22180306", "FullCitation": "Borger DR, et al. Oncologist (2012) pmid: 22180306", "Include": "true"}, {"number": "114", "ReferenceId": "10738270", "FullCitation": "Suto T, et al. J Surg Oncol (2000) pmid: 10738270", "Include": "true"}, {"number": "115", "ReferenceId": "22561520", "FullCitation": "Ong CK, et al. Nat. Genet. (2012) pmid: 22561520", "Include": "true"}, {"number": "116", "ReferenceId": "21538283", "FullCitation": "Nault JC, et al. Semin. Liver Dis. (2011) pmid: 21538283", "Include": "true"}, {"number": "117", "ReferenceId": "20955617", "FullCitation": "Won HS, et al. BMC Cancer (2010) pmid: 20955617", "Include": "true"}, {"number": "118", "ReferenceId": "16686942", "FullCitation": "Chaube A, et al. BMC Cancer (2006) pmid: 16686942", "Include": "true"}, {"number": "119", "ReferenceId": "15573254", "FullCitation": "Chuang SC, et al. World J Surg (2004) pmid: 15573254", "Include": "true"}, {"number": "120", "ReferenceId": "22230750", "FullCitation": "Xiaofang L, et al. World J Surg Oncol (2012) pmid: 22230750", "Include": "true"}, {"number": "121", "ReferenceId": "8799388", "FullCitation": "Ajiki T, et al. Hepatogastroenterology () pmid: 8799388", "Include": "true"}, {"number": "122", "ReferenceId": "16724348", "FullCitation": "J Surg Oncol (2006) pmid: 16724348", "Include": "true"}, {"number": "123", "ReferenceId": "24746206", "FullCitation": "Guo R, et al. Hum. Pathol. (2014) pmid: 24746206", "Include": "true"}, {"number": "124", "ReferenceId": "25536104", "FullCitation": "Churi CR, et al. PLoS ONE (2014) pmid: 25536104", "Include": "true"}, {"number": "125", "ReferenceId": "7567135", "FullCitation": "Lee CS, et al. Pathology (1995) pmid: 7567135", "Include": "true"}, {"number": "126", "ReferenceId": "11180865", "FullCitation": "Ahrendt SA, et al. J Hepatobiliary Pancreat Surg (2000) pmid: 11180865", "Include": "true"}, {"number": "127", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "128", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "129", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "130", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "131", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "132", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "133", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "134", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "135", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "136", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "137", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "138", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "139", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "140", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "141", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "142", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "143", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "144", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "145", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "146", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "147", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "148", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "149", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "150", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "151", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "152", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "153", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "154", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "155", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "156", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "157", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "158", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "159", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "160", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "161", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "162", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "163", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "164", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "165", "ReferenceId": "31602320", "FullCitation": "Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320", "Include": "true"}, {"number": "166", "ReferenceId": "32757294", "FullCitation": "Zhang EW, et al. Cancer (2020) pmid: 32757294", "Include": "true"}, {"number": "167", "ReferenceId": "30833418", "FullCitation": "Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418", "Include": "true"}, {"number": "168", "ReferenceId": "24553385", "FullCitation": "Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385", "Include": "true"}, {"number": "169", "ReferenceId": "30400802", "FullCitation": "Lapin M, et al. J Transl Med (2018) pmid: 30400802", "Include": "true"}, {"number": "170", "ReferenceId": "30131550", "FullCitation": "Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550", "Include": "true"}, {"number": "171", "ReferenceId": "30385733", "FullCitation": "Choudhury AD, et al. JCI Insight (2018) pmid: 30385733", "Include": "true"}, {"number": "172", "ReferenceId": "29298117", "FullCitation": "Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117", "Include": "true"}, {"number": "173", "ReferenceId": "30793095", "FullCitation": "Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095", "Include": "true"}, {"number": "174", "ReferenceId": "31059681", "FullCitation": "Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681", "Include": "true"}, {"number": "175", "ReferenceId": "28187169", "FullCitation": "Fan G, et al. PLoS ONE (2017) pmid: 28187169", "Include": "true"}, {"number": "176", "ReferenceId": "30923679", "FullCitation": "Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679", "Include": "true"}, {"number": "177", "ReferenceId": "30093454", "FullCitation": "Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454", "Include": "true"}, {"number": "178", "ReferenceId": "30860573", "FullCitation": "Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573", "Include": "true"}, {"number": "179", "ReferenceId": "28450425", "FullCitation": "Goodall J, et al. Cancer Discov (2017) pmid: 28450425", "Include": "true"}, {"number": "180", "ReferenceId": "29330207", "FullCitation": "Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207", "Include": "true"}, {"number": "181", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "182", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "183", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "184", "ReferenceId": "11580146", "FullCitation": "Momoi H, et al. J. Hepatol. (2001) pmid: 11580146", "Include": "true"}, {"number": "185", "ReferenceId": "12175538", "FullCitation": "Limpaiboon T, et al. Cancer Lett. (2002) pmid: 12175538", "Include": "true"}, {"number": "186", "ReferenceId": "12402306", "FullCitation": "Liu D, et al. Int. J. Cancer (2002) pmid: 12402306", "Include": "true"}, {"number": "187", "ReferenceId": "14506736", "FullCitation": "Liengswangwong U, et al. Int. J. Cancer (2003) pmid: 14506736", "Include": "true"}, {"number": "188", "ReferenceId": "17204026", "FullCitation": "Histopathology (2007) pmid: 17204026", "Include": "true"}, {"number": "189", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "190", "ReferenceId": "28734759", "FullCitation": "Overman MJ, et al. Lancet Oncol. (2017) pmid: 28734759", "Include": "true"}, {"number": "191", "ReferenceId": "29355075", "FullCitation": "Overman MJ, et al. J. Clin. Oncol. (2018) pmid: 29355075", "Include": "true"}, {"number": "192", "ReferenceId": "23169436", "FullCitation": "Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436", "Include": "true"}, {"number": "193", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "194", "ReferenceId": "33001143", "FullCitation": "Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143", "Include": "true"}, {"number": "195", "ReferenceId": "31088831", "FullCitation": "Bahleda R, et al. Clin. Cancer Res. (2019) pmid: 31088831", "Include": "true"}, {"number": "196", "ReferenceId": "28341788", "FullCitation": "Perera TPS, et al. Mol. Cancer Ther. (2017) pmid: 28341788", "Include": "true"}, {"number": "197", "ReferenceId": "28416604", "FullCitation": "Karkera JD, et al. Mol. Cancer Ther. (2017) pmid: 28416604", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_03_06 15:08:36", "OpName": "Eric Severson, M.D., Ph.D., M.M.Sc. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Eric Severson, M.D., Ph.D., M.M.Sc. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "N/A"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "1 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "18%"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "LIVER", "disease_ontology": "Liver cholangiocarcinoma", "flowcell_analysis": "2000020522", "gender": "female", "pathology_diagnosis": "Cholangiocarcinoma", "pipeline_version": "v3.10.1", "purity_assessment": "27.0", "specimen": "ORD_1310401_01*US1259521.01", "study": "CLINICAL_F1LCDx", "test_request": "ORD_1310401_01", "test_type": "FoundationOneLiquidDx", "tissue_of_origin": "Blood", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "AB1", "name": "SQ_US1259521.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4056", "cds_effect": "2228G>C", "depth": "1366", "equivocal": "false", "functional_effect": "missense", "gene": "TEK", "percent_reads": "40.56", "position": "chr9:27204927", "protein_effect": "G743A", "status": "unknown", "strand": "+", "transcript": "NM_000459", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.012", "cds_effect": "3475G>C", "depth": "581", "equivocal": "false", "functional_effect": "missense", "gene": "TET2", "percent_reads": "1.2", "position": "chr4:106162561", "protein_effect": "A1159P", "status": "unknown", "strand": "+", "transcript": "NM_001127208", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.1224", "cds_effect": "1377_1378insC", "depth": "629", "equivocal": "false", "functional_effect": "frameshift", "gene": "ARID1A", "percent_reads": "12.24", "position": "chr1:27057669", "protein_effect": "S460fs*163", "status": "likely", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.2026", "cds_effect": "451C>T", "depth": "4447", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "20.26", "position": "chr17:7578479", "protein_effect": "P151S", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.495", "cds_effect": "280C>A", "depth": "5941", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "49.5", "position": "chr5:112102945", "protein_effect": "R94S", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.4978", "cds_effect": "3482C>T", "depth": "5575", "equivocal": "false", "functional_effect": "missense", "gene": "CDK12", "percent_reads": "49.78", "position": "chr17:37682291", "protein_effect": "T1161M", "status": "unknown", "strand": "+", "transcript": "NM_016507", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.4769", "cds_effect": "527_528insAGC", "depth": "281", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "GATA4", "percent_reads": "47.69", "position": "chr8:11566348", "protein_effect": "A179_S180insA", "status": "unknown", "strand": "+", "transcript": "NM_002052", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.8919", "cds_effect": "886C>T", "depth": "444", "equivocal": "false", "functional_effect": "missense", "gene": "MSH3", "percent_reads": "89.19", "position": "chr5:79968156", "protein_effect": "R296C", "status": "unknown", "strand": "+", "transcript": "NM_002439", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"allele_fraction": "0.0029", "cds_effect": "425T>C", "depth": "1706", "equivocal": "false", "functional_effect": "missense", "gene": "CXCR4", "percent_reads": "0.29", "position": "chr2:136873085", "protein_effect": "I142T", "status": "unknown", "strand": "_", "transcript": "NM_001008540", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": {"description": "FGFR2(NM_000141)_BICC1(NM_001080512) fusion (F17; B3)", "equivocal": "false", "in_frame": "Yes", "other_gene": "BICC1", "percent_reads": "28.11", "pos1": "chr10:123239679", "pos2": "chr10:60420186", "status": "known", "supporting_read_pairs": "835", "targeted_gene": "FGFR2", "type": "fusion", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "1.26", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": {"non_human": [{"organism": "HPV_16", "reads_per_million": "60", "status": "unknown", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"organism": "HHV_8", "reads_per_million": "22", "status": "unknown", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}, {"organism": "HHV_4", "reads_per_million": "61", "status": "unknown", "dna_evidence": {"sample": "SQ_US1259521.01_1"}}]}}}}}